Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDHI R132 mutation effects in human glioblastoma

Journal of Histochemistry and Cytochemistry

Volumn 59, Issue 5, 2011, Pages 489-503

  Atai, Nadia A ^a   Renkema Mills, Nynke A ^a   Bosman, Joost ^a   Schmidt, Nadja ^a   Rijkeboer, Denise ^a   Tigchelaar, Wikky ^a   Bosch, Klazien S ^a   Troost, Dirk ^a   Jonker, Ard ^a   Bleeker, Fonnet E ^c   Miletic, Hrvoje ^b   Bjerkvig, Rolf ^b   de Witt Hamer, Philip C ^c   van Noorden, Cornelis J F ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF BERGEN   (Norway)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

dehydrogenase; G6PDH; Glioblastoma; IDH1; In silico analysis; Metabolic mapping; Mutation; NADPH

Indexed keywords

ISOCITRATE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OXIDOREDUCTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DETOXIFICATION; DISEASE ASSOCIATION; GENE EXPRESSION; GLIOBLASTOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL; THYROID GLAND; TUMOR GENE; ANIMAL; ANIMAL MODEL; BIOSYNTHESIS; BRAIN TUMOR; C57BL MOUSE; ENZYMOLOGY; GENETICS; HUMAN; MUTATION; NUDE RAT;

RODENTIA;

ANIMALS; BRAIN; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MUTATION; NADP; OXIDOREDUCTASES; RATS; RATS, NUDE;

EID: 79958822681     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155411400606     Document Type: Article

References (99)

1. Abdel-Wahab O, Levine RL. 2010. Metabolism and the leukemic stem cell. J Exp Med. 207:677-680.
2. Aghili M, Zahedi F, Rafiee E. 2009. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J Neurooncol. 91:233-236.
3. Andrulis M, Capper D, Luft T, Hartmann C, Zentgraf H, Von Deimling A. 2010. Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutationspecific antibody and direct sequencing. Leukemia Res. 34:1091-1093.
4. Atai NA, Bosch KS, Bansal M, Lo C, Bosman J, Tigchelaar W, Jonker A, De Witt Hamer PC, Troost D, McCulloch CA, et al. 2011. Osteopontin is upregulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology. 132:39-48.
5. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, Von Deimling A. 2008. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116:597-602.
6. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al. 2002. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 8:816-824.
7. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et al. 2001. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 98:13790-13795.
8. Biaglow JE, Miller RA. 2005. The thioredoxin reductase/ thioredoxin system. Cancer Biol Ther. 4:6-13.
9. Biagotti E, Bosch KS, Ninfali P, Frederiks WM, Van Noorden CJF. 2000. Postranslational regulation of glucose-6-phosphate dehydrogenase activity in tongue epithelium. J Histochem Cytochem. 48:971-977.
10. Biagotti E, Ferri P, Dringen R, Del Grande P, Ninfali P. 2005. Glucose-6-phosphate dehydrogenase and NADPH-consuming enzymes in the rat olfactory bulb. J Neurosci Res. 80:434-441.
11. Biagotti E, Malatesta M, Capellacci S, Fattoretti P, Gazzanelli G, Ninfali P. 2002. Quantification of G6PD in small and large intestine of rat during aging. Acta Histochem. 104:225-234.
12. Bjerkvig R, Johansson M, Miletic H, Niclou SP. 2009. Cancer stem cells and angiogenesis. Semin Cancer Biol. 19:279-284.
13. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, Tigchelaar W, Troost D, Vandertop WP, Bardelli A, et al. 2010. The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 119:487-494.
14. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, et al. 2009. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 30:7-11.
15. Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, et al. 2010. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the acute leukemia French association group. J Clin Oncol. 28:3717-3723.
16. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI. 2005. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 65:8679-8689.
17. Butcher RG, Van Noorden CJF. 1985. Reaction rate studies of glucose-6-phosphate dehydrogenase activity in sections of rat liver using four tetrazolium salts. Histochem J. 17:993-1008.
18. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, et al. 2002. Gene expression patterns in human liver cancers. Mol Biol Cell. 13:1929-1939.
19. Chen X, Leung SY, Yuen ST, Chu KM, Ji J, Chan AS, Law S, Troyanskaya OG, Wong J, et al. 2003. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell. 14:3208-3215.
20. Chieco P, Jonker A, Melchiorri C, Vanni G, Van Noorden CJF. 1994. A user's guide for avoiding errors in absorbance image cytometry: a review with original experimental observations. Histochem J. 26:1-19.
21. Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, Hsu SC, et al. 2010. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood. 115:2749-2754.
22. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, et al. 2004. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 5:489-500.
23. Cromer A, Carles A, Millon R, Ganguli G, Chalmal F, Lemaire F, Young J, Dembélé D, Thibault C, Muller D, et al. 2004. Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene. 23:2484-2498.
24. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Kennan MC, et al. 2009. Cancerassociated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462:739-747.
25. Dehan E, Ben-Dor A, Liao W, Lipson D, Frimer H, Rienstein S, Simansky D, Krupsky M, Yaron P, Friedman E, et al. 2007. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer. 56:175-184.
26. De Witt Hamer PC, Bleeker FE, Zwinderman AH, Van Noorden CJF. 2006. Can you trust your cryostat? Reproducibility of cryostat section thickness. Microsc Res Techn. 69:835-838.
27. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. 2001. Delineation of prognostic biomarks in prostate cancer. Nature. 412:822-826.
28. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Lensen JL, Moller K, Orntoft TF. 2004. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64:4040-4048.
29. Ferri P, Biagotti E, Ambrogini P, Santi S, Del Grande P, Ninfali N. 2005. NADPH-consuming enzymes correlate with glucose-6- phosphate dehydrogenase in Purkinje cells: an immunohistochemical and enzyme histochemical study of the rat cerebellar cortex. Neurosci Res. 51:185-195.
30. Fu Y, Huang R, Du J, Yang R, An N, Liang A. 2010. Gliomaderived mutations in IDH: from mechanism to potential therapy. Biochem Biophys Res Commun. 397:127-130.
31. Geisbrecht BV, Gould SJ. 1999. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem. 274:30527-30533.
32. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ, et al. 2005. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 166: 1827-1840.
33. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, et al. 2010. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 207:339-344.
34. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M Schackert G, Meyermann R, Pietsch T, et al. 2010. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 120:707-718.
35. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, et al. 2009. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 118:469-474.
36. Higgins JP, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, Fero M, Pollack JR, van de Rijn M, Brooks D. 2003. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol. 162:925-932.
37. Hippo Y, Taniguchi H, Tsutsumi S, Machida N, Chong JM, Fukayama M, Kodama T, Aburatani H. 2002. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res. 62:233-240.
38. Holmgren A, Lu J. 2010. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun. 396:120-124.
39. Houillier C, Wang X, Kaloshi G, Moktari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, et al. 2010. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 75:1560-1566.
40. Hughes JM, Groot AJ, Van der Groep P, Sersansie R, Vooijs M, Van Diest PJ, Van Noorden CJF, Schlingemann RO, Klaassen I. 2010. Active HIF-1 in the normal human retina. J Histochem Cytochem. 58:247-254.
41. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, Collins VP. 2009. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-Oncology. 11:341-347.
42. Inamura K, Fujiwara T, Hoshida Y, Isagawa T, Jones MH, Virtanen C, Shimane M, Satoh Y, Okamura S, Nakagawa K, et al. 2005. Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. Oncogene. 24:7105-7113.
43. Kil IS, Huh TL, Lee YS, Lee YM, Park JW. 2006. Regulation of replicative senescene by NADP+-dependent isocitrate dehydrogenase. Free Radic Biol Med. 40:110-119.
44. Kil IS, Kim SY, Lee SJ, Park JW. 2007. Small interfering RNAmediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-a and anticancer drugs. Free Radic Biol Med. 43:1197-1207.
45. Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, Hart J. 2005. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 65:3146-3154.
46. Koehler A, Van Noorden CJF. 2003. Reduced nicotinamide adenine dinucleotide phosphate and the higher incidence of pollution-induced liver cancer in female flounder. Environ Toxicol Chem. 22:2703-2710.
47. Korkola JE, Houldsworth J, Chadalavada RS, Olshen AB, Dobrzynski D, Reuter VE, Bosl GJ, Chaganti RS. 2006. Downregulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res. 66:820-827.
48. Kotliarov Y, Steed ME, Christopher N, Walling J, Su Q, Center A, Heiss J, Rosenblum M, Mikkelsen T, Zenklusen JC, et al. 2006. High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res. 66:9428-9436.
49. Kuriakose MA, Chen WT, He ZM, Sikora AG, Zhang P, Zhang ZY, Qiu WL, Hsu DF, McMunn-Coffran C, Brown SM, et al. 2004. Selection and validation of differentially expressed genes in head and neck cancer. Cell Mol Life Sci. 61:1372-1383.
50. Lapointe J, Li C, Higgins JP, Van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al. 2004. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 101:811-816.
51. Lee AM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW. 2002. Cytosolic NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med. 32:1185-1196.
52. Lenburg ME, Liou LS, Gerry NP, Framton GM, Cohen HT, Christman MF. 2003. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer. 3:31.
53. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, et al. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 361:1058-1066.
54. Margittai E, Banhegyi G. 2008. Isocitrate dehydrogenase: a NADPH-generating enzyme in the lumen of the endoplasmic reticulum. Arch Biochem Biophys. 471:184-190.
55. Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AAG, Zwinderman AH, Geerts D, Kaspers GJ, et al. 2010. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 18:244-257.
56. Murugan AK, Bojdani E, Xing M. 2010. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun. 393:555-559.
57. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. 2009. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 15:6002-6007.
58. Notterman DA, Alon U, Sierk AJ, Levine AJ. 2001. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 61:3124-3130.
59. Ohgaki H, Kleihues. 2009. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 100:2235-2241.
60. Ozben T. 2007. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci. 96:2181-2196.
61. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807-1812.
62. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, et al. 2010. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 28:3636-3643.
63. Perou CM, Sørlie T, Eisen MB, Van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. 2000. Molecular portraits of human breast tumours. Nature. 406:747-752.
64. Peters AL, Van Noorden CJF. 2009. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. J Histochem Cytochem. 57:1003-1011.
65. Pollard PJ, Ratcliffe PJ. 2009. Puzzling patterns of predisposition. Science. 324:192-194.
66. Quade BJ, Wang TY, Sornberger K, Dal CP, Mutter GL, Morton CC. 2004. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer. 40:97-108.
67. Rasband WS. 2009. ImageJ. http://rsbweb.nih.gov/ij.
68. Reitman ZJ, Yan H. 2010. Isocitrate dehydrogenase 1 and 2 mutations in cancer: altenations at a crossroads of cellular metabolism. J Natl Cancer Inst. 102:932-941.
69. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. 2006. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 9:121-132.
70. Salvemini F, Franze A, Iervolino A, Filosa S, Salzano S, Ursini MV. 1999. Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression. J Biol Chem. 274:2750-2757.
71. Sanson M, Marie Y, Paris S, Idbaith A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, et al. 2009. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 27:4150-4154.
72. Scott MD, Zuo L, Lubin BH, Chiu DYT. 1991. NADPH, not glutathione status modulates oxidant sensitivity in normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. Blood. 77:2059-2064.
73. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, et al. 2010. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 70:8981-8987.
74. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, et al. 2002. Gene expression correlates of clinical prostate cancer behaviour. Cancer Cell. 1:203-209.
75. Sonoda Y, Kumabe T, Nakamura T, Saits R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T. 2009. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 100:1996-1998.
76. Sperger JM, Chen X, Draper JS, Antosiewicz JE, Chon CH, Jones SB, Brooks JD, Andrews PW, Brown PO, Thomson JA. 2003. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci U S A. 100:13350-13355.
77. Stoward PJ, Meijer AEFH, Seidler E, Wohlrab F. 1991. Dehydrogenases. In Stoward PJ, Pearse AGE, eds. Histochemistry. Vol 3, 4th ed. Edinburgh, UK: Churchill Livingstone.
78. Stoward PJ, Van Noorden CJF. 1991. Histochemical methods for dehydrogenases. In Stoward PJ, Pearse AGE, eds. Histochemistry. Vol 3, 4th ed. Edinburgh, UK: Churchill Livingstone.
79. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D, Wang Y. 2005. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 11:7234-42.
80. Thompson CB. 2009. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med. 360:813-815.
81. Van Noorden CJF. 1984. Histochemistry and cytochemistry of glucose-6-phosphate dehydrogenase. Progr Histochem Cytochem. 15(4):1-85.
82. Van Noorden CJF. 2009. Metabolic mapping by enzyme histochemistry in living animals, tissues and cells. J Physiol Pharmacol. 60(Suppl 4):125-129.
83. Van Noorden CJF. 2010. Imaging enzymes at work: metabolic mapping by enzyme histochemistry. J Histochem Cytochem. 58:481-497.
84. Van Noorden CJF, Butcher RG. 1986. A quantitative histochemical study of NADPH-ferrihemoprotein reductase activity. Histochem J. 18:364-370.
85. Van Noorden CJF, Butcher RG. 1991. Quantitative enzyme histochemistry. In Stoward PJ, Pearse AGE, eds. Histochemistry. Vol 3, 4th ed. Edinburgh, UK: Churchill Livingstone.
86. Van Noorden CJF, Frederiks WM. 1992. Enzyme histochemistry: a laboratory manual of current methods. Oxford, UK: Oxford Science Publications.
87. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al. 2005. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 8:393-406.
88. Vischer N, Nastase S. 2009. ObjectJ. http://simon.bio.uva.nl/.
89. Vogels IMC, Hoeben KA, Van Noorden CJF. 2009. Rapid combined light and electron microscopy on large frozen biological samples. J Microsc. 235:252-258.
90. Wachi S, Yoneda K, Wu R. 2005. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics. 21:4205-4208.
91. Wang J, Miletic H, Sakariassen PØ, Huszthy PC, Jacobsen H, Brekkå N, Li X, Zhao P, Mørk S, Chekenya M, et al. 2009. A reproducible brain tumor model established from human glioblastoma biopsies. BMC Cancer. 9:465.
92. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, et al. 2010. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting a-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 17: 225-234.
93. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. 2009. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153.
94. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, et al. 2009. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German glioma network. J Clin Oncol. 27:5743-5750.
95. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. 2001. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A. 98:1176-1181.
96. Xu X, Zhao J, Xu Z, Peng B, Huang Q, Arnold E, Ding J. 2004. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem. 279:33946-33957.
97. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos J, Batinic-Haberle I, Jones S, Riggins GJ, et al. 2009. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765-773.
98. Ying W. 2008. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal. 10:179-206.
99. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peny Y, et al. 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1a. Science 324:261-265.